FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386592053> ?p ?o ?g. }

• W4386592053 abstract "Abstract Real-world studies permit inclusion of a more diverse patient population and provide more information on the effectiveness of treatments used in routine clinical practice. This prospective, multicenter, observational study investigated the effectiveness and safety of ixazomib plus lenalidomide and dexamethasone (IRd) in 295 patients with relapsed/refractory multiple myeloma (RRMM) in routine clinical practice in Japan. Patients had a median age of 74 years, 80.0% were aged ≥ 65 years, 42.0% had received ≥ 3 lines of prior treatment, and 28.5% were “frail” according to the International Myeloma Working Group frailty score. After a median follow-up of 25.0 months, median progression-free survival (PFS) was 15.3 (95% CI 12.4–19.5) months, while median overall survival was not reached. The overall response rate was 53.9%, and 31.5% of patients had a very good partial response or better. In the subgroup analysis, median PFS was better in patients with 1 versus 2 or ≥ 3 lines of prior treatment (29.0 vs 19.2 or 6.9 months) and paraprotein versus clinical relapse (16.0 vs 7.9 months), but median PFS was not notably affected by frailty score or age group. Dose adjustment was more frequent among patients aged > 75 years, especially early after IRd treatment initiation. Treatment-emergent adverse events (TEAEs) of any grade occurred in 84.4% of patients and 24.7% of patients discontinued treatment due to TEAEs; no new safety concerns were found. These findings suggest that oral IRd triplet regimen is an effective and tolerable treatment option for RRMM patients in real-world settings outside of clinical trials. ClinicalTrials.gov identifier: NCT03433001; Date of registration: 14 February 2018." @default.
• W4386592053 created "2023-09-12" @default.
• W4386592053 creator A5006710981 @default.
• W4386592053 creator A5007129211 @default.
• W4386592053 creator A5010152323 @default.
• W4386592053 creator A5012540836 @default.
• W4386592053 creator A5013980586 @default.
• W4386592053 creator A5019439008 @default.
• W4386592053 creator A5021001338 @default.
• W4386592053 creator A5021620288 @default.
• W4386592053 creator A5025340212 @default.
• W4386592053 creator A5030124286 @default.
• W4386592053 creator A5030594119 @default.
• W4386592053 creator A5034343487 @default.
• W4386592053 creator A5034503817 @default.
• W4386592053 creator A5034882455 @default.
• W4386592053 creator A5035237919 @default.
• W4386592053 creator A5036112859 @default.
• W4386592053 creator A5041678137 @default.
• W4386592053 creator A5050748706 @default.
• W4386592053 creator A5056294010 @default.
• W4386592053 creator A5056325706 @default.
• W4386592053 creator A5060126327 @default.
• W4386592053 creator A5078839273 @default.
• W4386592053 creator A5078852881 @default.
• W4386592053 creator A5085648676 @default.
• W4386592053 creator A5088707445 @default.
• W4386592053 date "2023-09-11" @default.
• W4386592053 modified "2023-09-29" @default.
• W4386592053 title "A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan" @default.
• W4386592053 cites W1985864219 @default.
• W4386592053 cites W2109371953 @default.
• W4386592053 cites W2201190784 @default.
• W4386592053 cites W2235535864 @default.
• W4386592053 cites W2288701630 @default.
• W4386592053 cites W2343386476 @default.
• W4386592053 cites W2486629951 @default.
• W4386592053 cites W2509578420 @default.
• W4386592053 cites W2528329272 @default.
• W4386592053 cites W2766948867 @default.
• W4386592053 cites W2771843848 @default.
• W4386592053 cites W2781388087 @default.
• W4386592053 cites W2888859046 @default.
• W4386592053 cites W2899308628 @default.
• W4386592053 cites W2899675310 @default.
• W4386592053 cites W2920787201 @default.
• W4386592053 cites W2979728113 @default.
• W4386592053 cites W2980869668 @default.
• W4386592053 cites W2983649595 @default.
• W4386592053 cites W3012199294 @default.
• W4386592053 cites W3015023972 @default.
• W4386592053 cites W3096176550 @default.
• W4386592053 cites W3097856484 @default.
• W4386592053 cites W3120704454 @default.
• W4386592053 cites W3138360017 @default.
• W4386592053 cites W3162052183 @default.
• W4386592053 cites W3166204225 @default.
• W4386592053 cites W3200319023 @default.
• W4386592053 cites W3204739494 @default.
• W4386592053 cites W4226014454 @default.
• W4386592053 cites W4285386088 @default.
• W4386592053 cites W4307327613 @default.
• W4386592053 cites W4308791219 @default.
• W4386592053 doi "https://doi.org/10.1007/s00277-023-05428-7" @default.
• W4386592053 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37695378" @default.
• W4386592053 hasPublicationYear "2023" @default.
• W4386592053 type Work @default.
• W4386592053 citedByCount "0" @default.
• W4386592053 crossrefType "journal-article" @default.
• W4386592053 hasAuthorship W4386592053A5006710981 @default.
• W4386592053 hasAuthorship W4386592053A5007129211 @default.
• W4386592053 hasAuthorship W4386592053A5010152323 @default.
• W4386592053 hasAuthorship W4386592053A5012540836 @default.
• W4386592053 hasAuthorship W4386592053A5013980586 @default.
• W4386592053 hasAuthorship W4386592053A5019439008 @default.
• W4386592053 hasAuthorship W4386592053A5021001338 @default.
• W4386592053 hasAuthorship W4386592053A5021620288 @default.
• W4386592053 hasAuthorship W4386592053A5025340212 @default.
• W4386592053 hasAuthorship W4386592053A5030124286 @default.
• W4386592053 hasAuthorship W4386592053A5030594119 @default.
• W4386592053 hasAuthorship W4386592053A5034343487 @default.
• W4386592053 hasAuthorship W4386592053A5034503817 @default.
• W4386592053 hasAuthorship W4386592053A5034882455 @default.
• W4386592053 hasAuthorship W4386592053A5035237919 @default.
• W4386592053 hasAuthorship W4386592053A5036112859 @default.
• W4386592053 hasAuthorship W4386592053A5041678137 @default.
• W4386592053 hasAuthorship W4386592053A5050748706 @default.
• W4386592053 hasAuthorship W4386592053A5056294010 @default.
• W4386592053 hasAuthorship W4386592053A5056325706 @default.
• W4386592053 hasAuthorship W4386592053A5060126327 @default.
• W4386592053 hasAuthorship W4386592053A5078839273 @default.
• W4386592053 hasAuthorship W4386592053A5078852881 @default.
• W4386592053 hasAuthorship W4386592053A5085648676 @default.
• W4386592053 hasAuthorship W4386592053A5088707445 @default.
• W4386592053 hasBestOaLocation W43865920531 @default.
• W4386592053 hasConcept C126322002 @default.
• W4386592053 hasConcept C141071460 @default.
• W4386592053 hasConcept C197934379 @default.
• W4386592053 hasConcept C207103383 @default.
• W4386592053 hasConcept C23131810 @default.

• next